Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by HealthInvest Partners AB

HealthInvest Partners AB grew its holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) by 46.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 247,454 shares of the company’s stock after purchasing an additional 78,932 shares during the period. HealthInvest Partners AB’s holdings in Cabaletta Bio were worth $554,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of CABA. Jennison Associates LLC lifted its position in Cabaletta Bio by 1.6% in the third quarter. Jennison Associates LLC now owns 5,632,681 shares of the company’s stock valued at $26,586,000 after buying an additional 86,214 shares during the last quarter. Fred Alger Management LLC raised its stake in shares of Cabaletta Bio by 63.3% in the 3rd quarter. Fred Alger Management LLC now owns 4,119,394 shares of the company’s stock valued at $19,444,000 after acquiring an additional 1,596,512 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Cabaletta Bio by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,094,644 shares of the company’s stock worth $5,168,000 after acquiring an additional 124,071 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Cabaletta Bio during the 3rd quarter worth approximately $3,150,000. Finally, Walleye Capital LLC increased its holdings in Cabaletta Bio by 111.6% in the 3rd quarter. Walleye Capital LLC now owns 401,982 shares of the company’s stock valued at $1,897,000 after purchasing an additional 212,025 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on CABA shares. Wells Fargo & Company cut Cabaletta Bio from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $12.00 to $6.00 in a research note on Thursday, December 19th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Cabaletta Bio in a report on Tuesday, February 18th. William Blair reissued an “outperform” rating on shares of Cabaletta Bio in a research report on Monday, November 18th. Evercore ISI lowered shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and lowered their price objective for the company from $15.00 to $6.00 in a research note on Friday, December 20th. Finally, TD Cowen raised shares of Cabaletta Bio to a “strong-buy” rating in a research note on Friday, November 29th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Cabaletta Bio has an average rating of “Buy” and an average price target of $22.71.

Cabaletta Bio Trading Down 2.2 %

Shares of CABA opened at $2.05 on Monday. The firm has a market capitalization of $99.96 million, a price-to-earnings ratio of -0.95 and a beta of 2.47. The firm’s fifty day simple moving average is $2.42 and its 200-day simple moving average is $3.54. Cabaletta Bio, Inc. has a twelve month low of $1.76 and a twelve month high of $24.85.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.